Clene Inc. (CLNN) · Oct 19, 2026 · Material agreement

Clene grant agreement extends ALS access, adds little new

$7.2M fourth-year subaward — Up to $7.2M for September 2026–August 2027

Clene’s grant agreement adds up to $7.2 million for year four of its ALS access program, extending support without changing the core story.

Clene is a late-stage biotechnology company developing CNM-Au8 for ALS and other neurodegenerative diseases, with its near-term story centered on seeking accelerated approval in ALS.

The filing extends an existing support program rather than changing the development story. Clene signed the fourth-year amendment for up to $7.2 million covering September 1, 2026 through August 31, 2027. The direction was already largely visible: the company had previously disclosed a four-year, $45.1 million NIH grant and successive annual subawards, so this is mainly confirmation of the final planned funding period.

The money supports patient access and data collection, not a new efficacy or regulatory milestone. The grant funds an Expanded Access Program for CNM-Au8 in ALS. 〔0〕 That helps sustain the program while Clene pursues its NDA, but the amendment itself supplies no new clinical results, FDA decision, or change to the drug’s approval odds.

Bottom line: This is useful operational continuity for Clene’s ALS program, but not a meaningful change to the investment story. The grant renewal is partly known and largely confirms funding already embedded in the company’s plan.

What to watch next

FDA review of CNM-Au8 NDA

Original filing on SEC EDGAR

More Clene Inc. news

Clene grant agreement extends ALS access, adds little new | CLNN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.